+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate whether giving plasma from a donor who had a Chikungunya infection within the past six months to newborns whose mothers had a peripartum Chikungunya infection can improve the chances that newborns survive without brain inflammation or damage within the first five days of life. The study compares this treatment group to an observational group of newborns who did not receive the plasma transfusion due to diagnosis or hospital transfer delays or parental refusal. Newborns in the treatment group receive a plasma transfusion and are monitored with medical and biological tests every day for the first seven days, plus a follow-up visit between one and three months of age. The observational group receives no intervention but has their medical data collected during standard care from the mothers diagnosis until the newborn reaches three months. Participants undergo daily clinical examinations and biological tests during the first week and one visit between one and three months. Researchers will measure the effectiveness of early plasma transfusion in preventing brain inflammation or damage within five days after inclusion. The study involves close monitoring and data collection to assess outcomes and safety over the newborns first few months.

Age: 0Days - 2DaysAll GendersPhase Not Applicable
3 locations
R

Actively Recruiting

Researchers are studying moderate facial acne in patients with darker skin tones, specifically Fitzpatrick skin types IV to VI. The study aims to compare the effects of oral isotretinoin as a first-line treatment versus the current standard care, which includes oral antibiotics and topical creams, focusing on the severity of acne-related pigmentation after six months. Acne affects about 9% of the global population and can impact quality of life, especially in people of color who often experience pigmentation issues linked to acne. Participants will be assigned to one of two groups. One group receives oral isotretinoin starting at 0.5 mgkgday, with possible dose adjustments based on tolerance and effectiveness over six months. The other group receives standard care, consisting of topical tretinoin or adapalene cream daily combined with doxycycline or lymecycline 100 mgday for three months, followed by assessment and possible continuation of topical treatment only. Participants in the isotretinoin group are followed monthly, while those in the standard care group have visits at 3 and 6 months. During the study, participants will be monitored for acne-related pigmentation severity, quality of life, and adverse events over six months. Assessments include clinical evaluations and self-photography using a smartphone with adequate camera resolution. Safety monitoring involves checking blood tests and pregnancy status for women of childbearing potential. The trial is randomized, open-label, and aims to enroll 420 participants aged 13 to 30 years with moderate acne and skin types IV to VI.

Age: 13Years - 30YearsAll GendersPhase 3
19 locations
S

Actively Recruiting

Healthy Volunteer

Peripheral neuropathies PN affect about 1% of people worldwide, especially older adults, causing problems with walking and chronic pain that reduce quality of life. In French Guiana, researchers think that unknown causes of PN may be linked to exposure to neurotoxic traditional plant remedies, arboviral infections like Zika, Chikungunya, and Dengue, and mercury contamination from illegal gold mining. This study aims to explore how these environmental factors relate to PN, including in people with diabetic neuropathy or chronic idiopathic axonal polyneuropathy. This is a prospective multicenter case-control study conducted at hospitals in Cayenne and Saint-Laurent du Maroni. Participants include patients with diagnosed diabetic peripheral neuropathy or chronic idiopathic axonal polyneuropathy, and a control group of hospital patients without neuropathy. At the initial visit, blood, urine, and hair samples will be collected to test for arbovirus antibodies and measure heavy metals like mercury and lead. Participants will also complete a questionnaire about their use of traditional plants. Participants will not have follow-up visits as part of the study. The main outcome measured is the comparison of exposure rates to these environmental factors between the case and control groups. Additional assessments include identifying genetic mutations and determining peripheral nerve disability at the time of enrollment. The study will help understand environmental risks that might explain unexplained cases of PN in this region.

Age: 18Years +All GendersPhase Not Applicable
2 locations
E

Actively Recruiting

Healthy Volunteer

The early months of a childs life are crucial for their long-term health, with breastfeeding playing a key role in healthy growth by reducing infant mortality and supporting brain development. This observational study in French Guiana aims to compare exclusive breastfeeding rates at one month between women who received health mediation support after childbirth and those who did not. The research builds on previous findings that many mothers face challenges to exclusive breastfeeding, especially those in vulnerable situations, and seeks to encourage breastfeeding practices that align with health recommendations. The study evaluates a health mediation program implemented in the maternity ward, where trained health mediators provide postpartum breastfeeding support tailored to each womans needs. This includes in-room assistance during the hospital stay, collaboration with healthcare teams, and participation in weekly breastfeeding workshops led by midwives or childcare assistants. Women in the exposed group receive this intervention, while the control group receives routine postpartum care without health mediation. Participants will be followed to assess exclusive breastfeeding rates at one month postpartum, along with secondary outcomes including breastfeeding duration, satisfaction with maternity care, breastfeeding support levels, and changes in breastfeeding practices and professional support over time. Data collection includes socioeconomic and medical information, health literacy, and self-efficacy related to breastfeeding. The study spans up to one year after intervention integration, with ongoing monitoring of maternal and professional practices to evaluate the programs feasibility and impact.

All AgesFEMALE
1 location
G

Actively Recruiting

Researchers are conducting a global registry to monitor the long-term safety and effectiveness of Increlex therapy in children and adolescents with Severe Primary Insulin-like Growth Factor-1 Deficiency SPIGFD. This observational, non-interventional registry collects data from multiple countries including Austria, France, Germany, Italy, Poland, Spain, Sweden, the United Kingdom, and the USA. The main goal is to gather safety information during treatment and for at least five years after treatment ends. The registry includes participants who are starting, planning to start, or already receiving Increlex treatment as per local prescribing information. Increlex mecasermin is given as an injection with doses ranging from 40 to 120 mcgkg twice daily, prescribed by a physician. Data may be collected retrospectively for those already on treatment. The study tracks participants over long periods to observe treatment exposure, dose, and various health outcomes related to growth and development. Participants will be monitored for adverse events, including serious events and neoplasia, during treatment and up to five years afterward. Researchers will also assess changes in height, bone age, body mass index, pubertal stage, and quality of life. Biological markers like growth hormone and IGF-1 levels will be measured periodically. The registry collects comprehensive data on safety, effectiveness, and other health indicators to better understand outcomes in children and adolescents receiving Increlex therapy.

Age: 2Years - 18YearsAll Genders
58 locations
P

Actively Recruiting

The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age. Participants will: * Take Hydroxycarbamide twice a day every day for 12 months * Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months

Age: 9Months - 11YearsAll GendersPhase 2
7 locations
E

Actively Recruiting

Researchers are studying chikungunya virus infection by evaluating the real-world effectiveness, safety, and immune response of two vaccines, IXCHIQ and VIMKUNYA, during an epidemic period in Runion Island and French Guiana. This ambispective Phase 4 study aims to provide insights into vaccine performance as defined by the French National Authority for Health HAS. Participants will be assigned to either a vaccinated group receiving IXCHIQ or VIMKUNYA vaccines or a non-vaccinated group. The study involves both retrospective and prospective components, including adults eligible for vaccination according to HAS criteria. All participants must consent and have French social security coverage. During the study, researchers will assess vaccine effectiveness at 6 months. Participants will be monitored for safety and immune response after vaccination. Data collection includes tracking vaccination status and health outcomes over the study period, which runs from April 2025 to December 2027.

Age: 18Years +All GendersPhase 4
2 locations
S

Actively Recruiting

Metabolic Dysfunction Associated Liver Disease MASLD is a common condition linked to metabolic syndrome, with genetic factors like PNPLA3 variants thought to influence liver fat buildup and damage. This research aims to study these genetic variations among MASLD patients in the overseas territories population, primarily of African descent mixed with European and Indian heritage, to better understand their susceptibility to developing the more severe form, Metabolic Dysfunction Associated Steatohepatitis MASH. The study will analyze genetic samples from adult MASLD patients seen in hospital departments in Guadeloupe, French Guiana, and Runion Island. Researchers will examine PNPLA3 polymorphisms and assess clinical, imaging, and laboratory markers of MASLD severity at the time of inclusion. This observational study does not involve interventions but focuses on collecting biological samples and health data to explore genetic and clinical profiles. Participants will provide informed consent and undergo assessments including liver imaging and blood tests to evaluate disease stage and fibrosis. Researchers will track allele frequencies of PNPLA3 variants and the distribution of liver disease severity at baseline. The study will also monitor laboratory biomarkers linked to MASLD. The total participation timeline aligns with the inclusion visit, with data collection focused on initial evaluation and genetic analysis.

Age: 18Years +All Genders
3 locations